Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: https://www.cellcentric.com/press-release/cellcentric-secures-35-million-investment-from-ra-capital-management/
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: https://www.cellcentric.com/press-release/cellcentric-secures-35-million-investment-from-ra-capital-management/
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: https://www.cellcentric.com/press-release/cellcentric-secures-35-million-investment-from-ra-capital-management/
